Emyria Limited is a clinical services and drug development company focused on improving patient outcomes in neuroscience and mental health via a unique business model:Emyria Clinics: Deliver evidence-based and emerging therapies for mental health and other unmet needs across multiple sites.Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients. Emyria Data is used to improve Emyria's distinct therapy and drug development programs.Emyria Drug Discovery: One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia and a suite of high potency Ultra-Pure cannabinoids currently being evaluated as in clinical trials for a range of mental health and select neuroscience indications.